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Abstract Application of a neuropsychological perspective
to the study of schizophrenia has established a number of
important facts about this disorder. Some of the key
findings from the existing literature are that, while neuro-
cognitive impairment is present in most, if not all, persons
with schizophrenia, there is both substantial interpatient
heterogeneity and remarkable within-patient stability of
cognitive function over the long-term course of the illness.
Such findings have contributed to the firm establishment of
neurobiologic models of schizophrenia, and thereby help to
reduce the social stigma that was sometimes associated with
purely psychogenic models popular during parts of the 20th
century. Neuropsychological studies in recent decades have
established the primacy of cognitive functions over psy-
chopathologic symptoms as determinants of functional
capacity and independence in everyday functioning. Al-
though the cognitive benefits of both conventional and even
second generation antipsychotic medications appear mar-
ginal at best, recognition of the primacy of cognitive
deficits as determinants of functional disability in schizo-
phrenia has catalyzed recent efforts to develop targeted
treatments for the cognitive deficits of this disorder. Despite
these accomplishments, however, some issues remain to be
resolved. Efforts to firmly establish the specific neuro-
cognitive/neuropathologic systems responsible for schizo-
phrenia remain elusive, as do efforts to definitively
demonstrate the specific cognitive deficits underlying
specific forms of functional impairment. Further progress
may be fostered by recent initiatives to integrate neuropsy-
chological studies with experimental neuroscience, perhaps
leading to measures of deficits in cognitive processes more
clearly associated with specific, identifiable brain systems.
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Introduction
Schizophrenia is now almost universally recognized as a
neurobiological disorder with a strong neurocognitive
component (Harrison and Weinberger 2005; Keshavan et
al. 2008). In contrast to earlier cognitive studies of
schizophrenia that were frequently focused on distinguish-
ing schizophrenia from “brain damage” (reviewed in
Heaton et al. 1978), or on the description of schizophrenic
thinking on a strictly psychological level (e.g., Bolles and
Goldstein 1938; Cameron 1939a, 1939b; Payne et al.1959;
Vigotsky 1934), an enormous and still growing body of
neuropsychological research on schizophrenia over the last
few decades has been based largely on either of two
premises: (a) specification of the neurocognitive pattern(s)
associated with schizophrenia may help clarify the neuro-
anatomic and/or neurophysiologic systems that underlie
expression of schizophrenia (Levin et al. 1989), and/or (b)
recognition that identifying cognitive strengths and weak-
nesses within persons with schizophrenia, and the relation-
ship of such cognitive abilities/deficits to psychosocial or
independent living functions, might prove clinically useful
in developing effective placement and rehabilitative plans
(Green 1996; Heaton 1976; Heaton and Pendleton 1981).
In this paper, we consider the recent empirical literature
to inform an overview of the neuropsychological aspects of
schizophrenia. Following some brief historical comments,
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we will focus the remainder of our review on the
following questions: (1) What cognitive domains are
affected by schizophrenia? (2) How much intragroup
heterogeneity exists? (Do all persons with schizophrenia
have cognitive impairment, and are there reliable cognitive
subtypes?) (3) What is the premorbid, peri-onset, and
long-term course of cognitive functioning in schizophre-
nia? (4) What is known about neuropathological systems
which may underlie cognitive dysfunction in schizophre-
nia? (5) What are the effects of general and specific
cognitive deficits on patients’ independence in everyday
functioning? and (6) What is the effectiveness of current
pharmacologic treatments for cognitive deficits in schizo-
phrenia? (We also briefly describe recent efforts to
develop non-pharmacologic interventions for the cognitive
deficits of schizophrenia; however, see Medalia and Choi
(2009), this volume, for a comprehensive review of
cognitive remediation in schizophrenia.)
Historical Evolution of Neurocognitive Models
of Schizophrenia
There is now overwhelming empirical evidence that
schizophrenia is fundamentally a neurobiologic disorder
(Harrison and Weinberger 2005; Keshavan et al. 2008), and
one that is at least usually (albeit, as discussed below,
perhaps not invariably) accompanied by neurocognitive
deficits (Dickinson et al. 2007; Fioravanti et al. 2005;
Heinrichs and Zakzanis 1998). Nevertheless, this contem-
porary view of the disorder represents a relatively recent
resolution of a sometimes heated debate over the past
century about the “functional” versus “organic” nature of
schizophrenia (Babcock 1933; Bleuler 1930; Leonberger
1989; May 1931; Paris 2005; Spielmeyer 1930; Walker and
Tessner 2008).
Emil Kraepelin, the first to distinguish schizophrenia
(dementia praecox) from other forms of serious mental
illness, held a strongly neurobiologic conceptualization of
this disorder. As early as 1899 he commented that “From
the known clinical and anatomical facts [of dementia
praecox] I cannot doubt that we have to do here with a
severe and as a rule markedly retrogressive process in the
brain cortex” (as translated and cited by May (1931)
p. 408). In the 1913 edition of his classic textbook,
Kraepelin (1971/1919/1913) discussed possible biological
as well as psychosocial causes of dementia praecox,
including a number of potential factors which anticipate
contemporary neurodevelopmental models of schizophrenia
(cf. Rapoport et al. 2005), such as hereditary predisposition
and “injury to the germ” (prenatal injury), as well as
commenting on minor facial and other physical anomalies
which exist “with striking frequency” among such patients
(p. 236). (The latter are currently thought to reflect parallel
prenatal aberrations in neurodevelopment (Weinberg et al.
2007).)
Anticipating that regions of interest in contemporary
neuroanatomic theories of schizophrenia would be focused,
in part, on the frontal-subcortical and temporal lobe
regions or systems (Harrison 2004; Ragland et al. 2007;
Shad et al. 2006; Winterer et al. 2003); Kraepelin (1971/
1919/1913) noted that “If it should be confirmed that the
disease attacks by preference the frontal areas of the brain,
the central convolutions, and the temporal lobes, this
distribution would in a certain measure agree with our
present views about the site of the psychic mechanisms
which are principally injured by this disease” (p. 219).
Kraepelin also characterized dementia praecox as a
dysfunction in what would today be labeled “executive
functions,” particularly in regard to deficits of “volition” or
“will” (see Zec 1995).
Despite such strong beginnings toward a neurobiologic
model of schizophrenia, the first half and even early second
half of the 20th century evidenced considerable debate
regarding psychogenic (or “functional”) versus biological
(“organic”) models of schizophrenia (Babcock 1933;
Bleuler 1930; Leonberger 1989; May 1931; Paris 2005;
Spielmeyer 1930; Walker and Tessner 2008). There were a
number of empirical reports documenting cognitive deficits
among persons with schizophrenia, particularly in regard to
deficits in abstraction, conceptualization, or a tendency
toward overgeneralization (e.g., Bolles and Goldstein 1938;
Cameron 1939b; Fey 1951; Payne et al. 1959; Rawlings
1921; Vigotsky 1934). With some exceptions (e.g.,
Babcock 1933; e.g., Rawlings 1921; Wittman 1937), the
latter tended to be focused on a purely psychological level
of description of the structure of schizophrenic thinking,
i.e., with limited presumption or reference to neuropatho-
logic mechanisms (see reviews by Lothrop (1961) and
Wright (1975)).
Even Kurt Goldstein, one of the pioneers of neuropsy-
chology and the use of psychometric tests to study the
effects of brain damage (see historical reviews by G.
Goldstein 1990a, 2009), and someone well aware of the
effects brain damage can have on abstraction ability
(Goldstein 1949; Goldstein and Scheerer 1941), empha-
sized the psychological, not neurobiologic, aspects of what
he called the impairment in “abstract attitude” among
persons with schizophrenia (Bolles and Goldstein 1938;
Goldstein 1939, 1959). Some of his musings about the
potential neuropathology underlying schizophrenia appear
remarkably contemporary. For example, he wrote that
“There is no doubt that the clinical picture of schizophrenia
contains symptoms which may best be understood as
expressions of a disturbed function of some apparatus of
the brain, particularly of the frontal lobes and the
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subcortical ganglia...” (Goldstein 1939, p. 582). Yet, his
emphasis in describing and explaining cognitive concrete-
ness in schizophrenia remained solidly on the psycholog-
ical/psychodynamic level. Indeed, in a later commentary, K.
Goldstein (1959) noted his opinion that the abnormal
concreteness in schizophrenia “is not the effect of an
organic defect” (italics in original; p. 147), but rather “a
protective mechanism against anxiety which originated in
early youth” (italics in original; p. 147).
As noted above, the other primary impetus in early and
mid-20th century studies of cognitive test performance in
schizophrenia was to identify test performance patterns that
would reliably discriminate patients with documented brain
lesions (“true organicity”) from those with schizophrenia
(reviewed in Heaton et al. 1978). Commenting on the
difficulties in finding useful discriminatory patterns,
Watson et al. (1968) wrote “It would appear that the chronic
schizophrenic’s motivational deficits and thought disorders,
coupled with the recovery shown by some organics, eliminate
many of the test differences psychologists have expected to
separate members of the two groups” (p. 679). The latter quote
demonstrates that, even through the late 1960s, at least some
researchers interpreted deficient performance by patients with
schizophrenia on neuropsychological tests as reflecting
deficits engaging in the tasks (due to psychotic symptoms
and motivation problems), rather than reflecting genuine
neurocognitive impairment.
Finally, in the last quarter of the 20th century,
neuropsychology began to take more frequent, albeit
initially somewhat diffident, steps in asserting the fact
that schizophrenia is fundamentally a brain disorder. For
instance, Strauss and Silverstein (1986) commented that
“Recent evidence has raised a question of a central
nervous system basis for schizophrenic psychopathology”
[underline added for emphasis] (p. 35). Although the
potential role of psychosocial stress in the phenotypic
manifestation of schizophrenia is still generally recog-
nized (Walker and Tessner 2008; Zubin and Spring 1977),
the last quarter century brought a clear, empirically
grounded change in the zeitgeist away from purely
psychogenic models of schizophrenia and other forms of
serious mental illness (Paris 2005; Walker and Tessner
2008). This change included an exponential growth in the
empirical study of schizophrenia from a neuropsycholog-
ical perspective (Levin et al. 1989).
Level and Domains of Cognitive Impairment
The extant neuropsychological literature relevant to estab-
lishing the level of cognitive impairment associated with
schizophrenia is truly enormous. Fortunately, there have
been a number of excellent meta-analytic reviews published
over the past decade, integrating the literature comparing
test performance among schizophrenia patients and healthy
comparison subjects (Dickinson et al. 2007; Fioravanti et
al. 2005; Heinrichs and Zakzanis 1998; Mesholam-Gately
et al. 2009). In addition to their own meta-analytic review
of individual studies, Dickinson et al. (2007) provided a
Table (i.e., their Table 4, p. 538) that serves as a summary
of meta-analytic reviews (see also Reichenberg and Harvey
2007). The general conclusion that can be drawn from this
literature is quite clear: schizophrenia is best characterized
as involving broad neurocognitive deficits across most
cognitive domains.
The average cognitive deficit associated with schizo-
phrenia appears to be approximately one standard deviation
(SD) below the mean of healthy comparison subjects
(Dickinson et al. 2007). In regard to specific cognitive
domains, the general trend in the literature seems to be
that the strongest effect sizes are associated with tests of
episodic memory (particularly free recall), and processing
speed, with the least (but still medium to large effect size
differences) associated with measures of crystallized
verbal knowledge and visual-spatial skill. For instance,
among studies reviewed by Heinrichs and Zakzanis
(1998), the lowest mean effect sizes were seen with the
Wechsler Block Design (d=0.46) and Vocabulary (d=0.53)
subtests; the strongest mean effect size was seen on tests of
“Global Verbal Memory” (d=1.41). Similarly, among studies
reviewed by Fioravanti et al. (2005), the largest effect sizes
were associated with tests of memory (d=1.18), and the
lowest with tests of language function (d=1.01) and global
cognitive function or IQ (d=1.01). In their recent meta-
analysis of studies of persons in their first-episode of
schizophrenia, Mesholam-Gately et al. (2009) also found
the largest effect sizes, on average, to be associated with tests
in the domain of auditory memory (d=1.20); although
among individual tests, the largest effect size was that for
Digit Symbol (d=1.59). The smallest effect sizes were in the
domain of motor speed and dexterity (d=0.64); although
on the level of individual test scores, some of the smallest
effect sizes were those associated with specific aspects of
California Verbal Learning Test Performance, particularly
“storage” (d=0.34). Dickinson et al. (2007) also found the
strongest effect sizes were those from the Digit Symbol task
(d=1.57), and auditory episodic memory tests tended to
have the next highest effect sizes (ds=1.09 to 1.25). Some
of the smallest effect sizes among studies reviewed by
Dickinson et al. (2007) were Block Design (d=0.84), Line
Orientation (d=0.62), and Word Reading (d=0.59). Yet,
note that even at the lower end, the effect size ranges in
these various reviews are near the cut-off of d=0.50
commonly labeled a “medium” effect, while many others
are above the d=0.80 cut-off commonly labeled as a
“large” effect size (Cohen 1988).
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In addition to memory impairment, there has been
considerable interest in the neuropsychological literature
focused on working memory and executive functions.
Among the meta-analyses reviewed by Dickinson et al.
(2007), the mean effect sizes for executive function tests
(Wisconsin Card Sorting Test, Stroop Color Word Interfer-
ence, and Trail Making Part B) range from d=0.53 to d=
1.06; for letter and category fluency (which were listed
separately), the effect sizes ranged from d=0.99 to 1.41;
and for working memory (including Digit Span forward and
backward, mental Arithmetic, Letter Number Sequencing,
and other measures of verbal or visual-spatial working
memory), the effect sizes ranged from 0.61 to 1.18. (For
sake of consistency, we have labeled the effect sizes with
“d” from Cohen’s d, but Dickinson et al. used a
modification which adjusts for small sample sizes,
Hedges’g). In short, although executive functions and
working memory are typically affected by schizophrenia,
the empirical data do not point to differential impairment in
these ability areas (Braff et al. 1991).
From the pattern of effect sizes reviewed above, one
might be tempted to conclude that episodic memory deficits
are in some sense an especially important or “core”
cognitive deficit in schizophrenia. However, the perennial
interpretive problem, brought by a lack of established
psychometric equivalence in sensitivity and specificity of
measures of different cognitive constructs, remains largely
unresolved (Chapman and Chapman 1973). Moreover, as
also is true of “attention” and “executive functions,” the
term “memory” is non-specific (Squire 2004). For instance,
it appears that the bulk of test scores contributing to the
large mean effect size for “memory,” reported in the studies
reviewed by Heinrichs and Zakzanis (1998), consisted of
free recall scores on tests of verbal episodic memory. In
stark contrast to the pattern seen with Alzheimer disease
(Tröster et al. 1993) patients with schizophrenia do not
typically show rapid forgetting of information actually
learned (Heaton et al. 1994; Paulsen et al. 1995). In a
meta-analysis specifically focused on memory test results,
Aleman et al. (1999) found an effect size for total recall of
d=1.21, whereas that for recognition scores was only half
as strong (d=0.64).
Further reason for caution in drawing conclusions about
differential “core” deficits was provided by Fioravanti et al.
(2005), who noted the considerable heterogeneity in effect
sizes seen between studies. (A similar observation was
made by Mesholam-Gately et al. (2009) in regard to studies
of first episode patients.) Fioravanti et al. (2005) attributed
the inter-study heterogeneity in effect sizes to both a lack of
cross-study consistency in methodology (including varia-
tion in the sensitivity of the specific measures employed to
operationalize various constructs, and variation in the
procedures for selecting and matching of healthy compar-
ison subjects), and to differences in the characteristics of
the patient samples. In regard to the latter, Fioravanti et
al. asserted that “Our analysis of heterogeneity indicates
that there has been a widespread failure to consider the
multidimensional nature of this patient population” (p. 90).
Thus, rather than endeavoring to establish the deficits of a
non-existent “average” patient with schizophrenia, it may
be more fruitful to consider the issue of cognitive
heterogeneity in level and pattern of impairment and the
factors which do or do not coaggregate with better/worse or
different patterns of impairment.
Heterogeneity
Do all persons with schizophrenia have cognitive impair-
ment? In the mid-1980s, there were several reports
indicating some patients with schizophrenia are “neuro-
psychologically intact” (Bryson et al. 1993; Silverstein
and Zerwic 1985; Strauss and Silverstein 1986), and more
recent studies indicate that approximately 15% to 30%
(with most estimates between 20% to 25%) of schizophre-
nia patients have neuropsychological profiles in the normal
range (Allen et al. 2003; Goldstein 1990b; Heinrichs and
Awad 1993; Holthausen et al. 2002; Ilonen et al. 2004;
Kremen et al. 2000; Leung et al. 2008; Liu et al. 2006;
Palmer et al. 1997; Weickert et al. 2000). For instance,
using a previously validated procedure for systematic
clinical ratings of results from an expanded Halstead-
Reitan battery (Heaton et al. 1981), we found 47 of the
171 (27.5%) people with schizophrenia had “neuropsycho-
logically normal” profiles (Palmer et al. 1997). By way of
comparison, Kremen et al. (2000) used a similar clinical
rating procedure, albeit with a different neuropsychological
test battery, and classified 17 of 75 (22.7%) schizophrenia
patients as “neuropsychologically within normal limits.”
The larger literature examining the association between
severity of cognitive deficits and psychopathologic symp-
toms is consistent in showing a significant but modest
association between severity of cognitive deficits and
negative symptoms, but no discernable association between
cognitive deficits and positive symptoms, such as halluci-
nations and delusions (see de Gracia Dominguez et al.
2009). Comparisons of neuropsychologically normal versus
neuropsychologically impaired patients with schizophrenia
yield results generally consistent with this overall pattern.
For instance, relative to neuropsychologically impaired
patients, the neuropsychologically normal patients in our
study had significantly less negative symptoms and
extrapyramidal symptoms, and reported more frequent
social contacts, as well as being less likely to have had a
psychiatric hospitalization in the year preceding evaluation
(Palmer et al. 1997). Other than the preceding variables,
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however, the neuropsychologically normal and impaired
patient groups were comparable in most of the demograph-
ic, symptomatic/clinical, and functional characteristics.
Similarly, Kremen et al. (2000) found that, relative to
neuropsychologically impaired patients, those who were
classified as “neuropsychologically within normal limits”
had a trend (p<.06) toward less negative symptoms, but no
difference in reality distortion or disorganized symptoms.
The neuropsychologically impaired patients in the latter
study also had worse mean scores on a global assessment of
psychosocial functioning, a lower proportion of paranoid
subtype, earlier age of onset, and longer duration of illness.
Leung et al. (2008) compared older schizophrenia patients
in terms of neuropsychologically normal status; they found
no significant differences among neuropsychologically
normal versus impaired patients in regard to overall
symptom status (or age).
Although the lack of group differences in severity of
positive symptoms suggests that neuropsychologically
normal status cannot be attributed to simple differences in
overall disease severity, “neuropsychologically normal
schizophrenia” is not necessarily synonymous with “neuro-
psychologically unaffected by schizophrenia” (Kremen et
al. 2000). As a group, neuropsychologically normal persons
with schizophrenia tend to have better than average
performances on word reading tasks and/or other measures
of crystallized verbal knowledge (Kremen et al. 2000; Wilk
et al. 2005), and/or other characteristics commonly used to
estimate “premorbid” functioning, such as maternal educa-
tion (Keefe et al. 2005). Based on such findings, some
investigators have suggested that “neuropsychologically
normal” schizophrenia patients have in fact experienced a
decline in cognitive functioning relative to an even higher
premorbid level or potential.
It should be noted that current above average perfor-
mance on tests of crystallized verbal ability, even relative to
one’s own other cognitive abilities, does not necessarily
indicate a pathological cognitive profile and/or that the non-
verbal abilities are below what they would be in the
absence of schizophrenia. For instance, Heinrichs et al.
(2008) compared the cognitive profiles of “verbally
superior” schizophrenia patients (defined by a WAIS-IIII
Vocabulary subtest Scaled Score ≥ 14) to those of verbally
superior healthy comparison subjects, as well as to verbally
not superior healthy comparison subjects and patients with
schizophrenia. The authors found no significant differences
in the mean cognitive profiles among the verbally superior
patients relative to the verbally superior healthy comparison
subjects. Educational history, another potential proxy for
premorbid function, was measured in reference to the
proportion of subjects who were high school graduates.
There were no significant differences in the high school
graduation rates among verbally superior patients (96%),
verbally superior comparison subjects (100%), or verbally
not superior comparison subjects (92%), whereas the
verbally not-superior patient group had a significantly
lower proportion of high school graduates (62%). As the
mean age of onset in both patient groups was approximate-
ly 20.6 years (with no significant differences between these
two groups), the lower rates of high school graduates
among the verbally not superior patients may simply reflect
the premorbid cognitive deficits often associated with this
disorder (discussed below). On the other hand, despite the
fact that verbally superior patients and comparison subjects
were equivalent in cognitive profiles and educational
background, this study found no significant differences
between the verbally superior and not verbally superior
patient groups in regard to severity of positive, negative, or
general symptoms, medication status, age of onset, or
current employment rates (the latter was lower in both
groups relative to the rates in both healthy comparison
groups). In short, verbally superior/neuropsychologically
normal status among schizophrenia patients did not equate
with less severe psychopathology or with less occupational
impairment.
Another potential method of examining the cognitive
deficits associated with the phenotypic manifestation of
schizophrenia is to study the degree of concordance in
cognitive functioning among monozygotic twins discordant
for schizophrenia. Reports of such data have been rare, but
the twin-pair level cognitive concordance rates were provid-
ed through one of the published reports from the NIMH
Twin Study. Specifically, Torrey et al. (1994) observed:
“... 3 of the 27 affected discordant twins were
severely neuropsychologically impaired, performing
significantly below their well co-twin on virtually all
tests. An additional 11 affected twins were moderately
impaired, performing significantly below their co-
twins on at least 2 of the 5 functions that most clearly
differentiated the affected twins (attention, memory,
problem-solving, information processing, and verbal
fluency)... Ten affected twins were less neuropsycho-
logically impaired, and 3 affected twins [11%]
showed minimal or no neuropsychological impair-
ment…some impairment in cognitive function, there-
fore, is present in almost all the affected twins with
schizophrenia and not just a small subgroup of them”
[underline added for emphasis] (p. 124).
The finding of three of 27 affected twins with minimal or
no neuropsychological impairment clearly represents too
small a sample to confidently or reliably estimate the
precise frequency of a population parameter, and the NIMH
investigators’ emphasis in the above quote was clearly on
the ubiquity of neurocognitive impairment in schizophre-
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nia. Nonetheless, the presence of the three of 27 affected
twins with “minimal or no neuropsychological impairment”
relative to the well co-twin is at least consistent with the
notion that some neuropsychologically normal patients may
in fact be functioning at or very close to the same level they
would have in the absence of manifesting the clinical
syndrome of schizophrenia. With the exception of an earlier
report of 16 twin pairs from the same NIMH Twin study
(Goldberg et al. 1990), to our knowledge, the only
published report to describe the overall cognitive concor-
dance rates among monozygotic twins discordance for
schizophrenia was that provided by Kremen et al. (2006).
They compared concordance in premorbid cognitive func-
tioning among 21 middle-aged monozygotic military
veteran twin pairs, currently discordant for schizophrenia,
all of whom had completed the Armed Forces Qualification
Test (AFQT) several decades earlier as part of their
induction into the military. They found that 67% of the
affected twins had lower (premorbid) AFQT scores than
their well twin. Stated another way, about one-third of
affected twins in monozygotic twin pairs discordant for
schizophrenia had a level of premorbid cognitive function
that was at least as good as that of their well twin.
Although the findings of Heinrichs et al. (2008),
described above, illustrate that the presence of a relative
strength in crystallized verbal knowledge is not synony-
mous with presence of even subtle deficits in other
neurocognitive domains relative to some hypothetical
higher potential level, it does seem likely that some
unknown proportion of “neuropsychologically normal”
people with schizophrenia do indeed manifest cognitive
skills at a level lower than they might have otherwise been
capable of in the absence of having developed schizophre-
nia. Thus, there may be two types of neuropsychologically
normal patients with schizophrenia: (a) some proportion,
such as the three of 27 affected twins in the NIMH twin
study (Torrey et al. 1994), who show no apparent decline
associated with the phenotypic expression of schizophrenia,
at least when tested with common neuropsychological
instruments, and (b) some proportion who have in fact
experienced a decline (within a published normal range on
the tests) relative to what the individual’s cognitive capacity
would have been in the absence of having developed
schizophrenia. The likely existence of the latter type of
neuropsychologically normal persons with schizophrenia
seems at least partially consistent with established theories
of brain or cognitive reserve (Satz 1993; Stern 2002). Yet,
based on those same cognitive or brain reserve theories, one
might ask: Why was there sufficient reserve to avoid
functionally disabling cognitive deficits, but insufficient
reserve to avoid functionally disabling psychopathologic
deficits? Empirical efforts to address such questions
through further fine-grained study of neuropsychologically
normal schizophrenia patients, perhaps using both structural
and functional neuroimaging methods, might provide
insights into still unresolved issues such as: (a) Which
neurobiologic systems underlie the cognitive deficits, which
underlie psychopathologic symptoms, and how much
overlap/separation is their between these systems? (b) Are
there identifiable “thresholds” of function/dysfunction in
these systems which predict whether or not disabling levels
of psychopathology and/or cognitive dysfunction are
expressed? and (c), Is there a causal link between some
forms of cognitive dysfunction and certain psychopatho-
logic symptoms, such as working memory deficits and
thought disorder (Goldman-Rakic 1994)?
A recent structural neuroimaging study by Wexler et al.
(2009) provides an illustrative example of how the concept
of “neuropsychologically normal schizophrenia” may prove
useful as part of ongoing efforts to elucidate the neuro-
pathological bases of schizophrenia in general. Using
structural MRI, these authors compared grey matter, white
matter, and ventricular volumes among 21 “neuropsycho-
logically near normal” persons with schizophrenia, 54
“neuropsychologically impaired” persons with schizophre-
nia, and 30 healthy comparison subjects. Both schizophre-
nia patient groups had smaller gray matter volumes and
larger third ventricles relative to healthy comparison
subjects. Compared to “neuropsychologically near normal”
schizophrenia patients, the neuropsychologically impaired
patients had smaller white matter volumes and larger lateral
ventricles. However, in several brain regions, the neuro-
psychologically near normal patients had smaller gray
matter volumes than the neuropsychologically impaired
patients. If replicated, such results may indicate that the
neuropathology associated with neuropsychologically nor-
mal schizophrenia represents a difference in kind/quality of
neuropathology, rather than a simple difference in degree or
severity of neuropathology.
As cogently argued by Allen et al. (2003), regardless of
whether neuropsychologically normal schizophrenia
patients have experienced slight declines from an even
higher potential or premorbid level, study of the nature of
(and factors underlying) manifest impairments in psycho-
social functioning may provide greater clarity in regard to
the non-cognitive contributions to impairment in everyday
functioning. A recent example of research efforts in this
vein was provided by the study of Leung et al. (2008), who
focused on the differences between neuropsychologically
normal versus impaired schizophrenia groups in reference
to three markers of “real world” functional status (indepen-
dent residential status, employment, and marital status), as
well as social competence and overall functional capacity
(measured via performance-based tasks). There were no
group differences in severity of psychopathology, but
relative to the neuropsychologically impaired patients,
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those who were neuropsychologically normal showed better
scores on a performance-based measure of social compe-
tence and a measure of overall functional capacity, and
were more likely to have independent living status. On the
other hand, there were no group differences in employment
or marital status. Note that findings regarding the lack of
effects of neuropsychologically normal profiles on work
status are consistent with those of Heinrichs et al. (2008),
described previously. We also obtained similar findings
from a study of predictors of functional status among
middle-aged and older patients with schizophrenia (Palmer
et al. 2002), i.e., there were significant correlations between
cognitive test performance and level of independence in
everyday functioning, but no significant correlation be-
tween cognitive performance and work history. Such
findings warrant follow-up through replication of the study,
but may indicate that work functioning is particularly
vulnerable to a variety of non-cognitive as well as cognitive
influences (cf. Green et al. 2000). The general issue of the
association of neuropsychological deficits with everyday
functioning is considered in greater detail in a separate
section to follow.
Cognitive subtypes: Another approach to the question of
cognitive heterogeneity in schizophrenia has been to use
cluster analyses to identify general cognitive subgroups.
Most cluster analytic studies (e.g. Allen et al. 1998;
Goldstein et al. 1998; Heinrichs and Awad 1993; Hill et
al. 2002; Horan and Goldstein 2003; Seaton et al. 1999)
find approximately four clusters that usually contain one
neuropsychologically normal cluster and one severely and
broadly impaired cluster. The other two clusters vary in
their profiles but are usually impaired (with differing
degrees of severity), and show perhaps one or two areas
of neuropsychological functioning as “stand out” impair-
ments (e.g., motor, verbal memory, or executive function-
ing). For example, Horan and Goldstein’s (2003) middle
two clusters included one described as moderate overall
impairment with severe motor impairment and the other
with moderate impairment in all areas, whereas Heinrichs
and Awad (1993) found five clusters with the three
intermediate clusters being described as (1) especially
impaired executive functioning, (2) especially impaired
executive functioning and motor abilities, and (3) especially
impaired motor abilities. Such findings are usually based on
some iterative procedure (e.g., Ward’s (1963) method) on
data that may have been reduced in some manner (e.g.,
principal components analysis) into neurocognitive
domains (e.g., abstraction/executive functioning, attention,
verbal and visual memory, verbal and visuospatial abilities,
motor skills, and working memory). However, there are
some interpretive limitations associated with cluster analy-
ses. The cluster determination may be arbitrary, depending
on the methods employed. Methods are varied and there is
little consensus as to the best method to employ, which may
lead to differing results (Lange et al. 2002). Also, the
clusters derived are often based upon overall level of
performance rather than pattern based, which in some
respects may not be very helpful in identifying “differences
in kind” (Lange et al. 2002). There are ongoing advances in
analytic techniques and approaches such as finite mixture
modeling or factor mixture modeling which have not been
widely applied to cognitive heterogeneity in schizophrenia
but may yield additional insights (McLachlan and Basford
1988).
When studies have examined the associations between
clinical or demographic factors and cluster membership,
most found that clinical characteristics (e.g. dose of
antipsychotic or positive or negative symptoms; Reich-
enberg and Harvey 2007) were not related, whereas some
demographics (e.g., education) were different between
clusters (Seaton et al. 1999). Heinrichs et al. (1997)
examined differences between cognitive cluster groups on
a modified version of the Sickness Impact Profile (SIP).
The SIP is a self-report measure that provides ratings of
self-perceived health, quality of life, sleep and rest, home
management, social interaction, and recreation activities.
The authors found that persons in the “normative”
(generally intact) cognitive group had better sleep and rest
relative to those in an “executive-motor” subtype (charac-
terized by impaired WCST and Purdue Pegboard scores),
whereas the selective executive group (characterized by
isolated impairment only on the WCST) reported better
home management, social interaction, and recreation than
the executive-motor group, as well as better social
interaction relative to those with generalized cognitive
impairment. However, the sample sizes for these analyses
were relatively small (total N=55); there is clearly a need
for additional research that is sufficiently powered to detect
functionally relevant differences and that employs multiple
measures of functional capacity and functional status. (The
issue of the association between cognitive deficits and
everyday functioning is considered in greater detail below.)
Allen et al. (2000) examined the relationship of
cognitive and symptom cluster subgroups to brain struc-
ture, measured with computerized tomography (CT) scans.
They found no significant differences among the cognitive
cluster groups in reference to ventricular size; however,
global sulcul widening was highest among patients in the
severely impaired cognitive cluster. In contrast, when
comparisons were made among symptom-based clusters,
participants in the predominantly negative symptoms
cluster had larger third ventricle diameters relative to
those in the mixed and positive symptom clusters. Allen et
al. concluded that symptom and cognitive abnormalities in
schizophrenia may have different neuropathological cor-
Neuropsychol Rev (2009) 19:365–384 371
relates. As also noted by Seaton et al. (2001): “Ultimately,
the most likely typology to be successful will involve a
combination of cognitive, symptom, and neuroimaging
variables” (p. 47).
Course
Premorbid cognitive functioning: There is compelling evi-
dence that schizophrenia is associated with early premorbid
cognitive deficits. For example, Bilder et al. (2006) compared
premorbid school transcripts, as well as college aptitude test
scores, from first-episode inpatients with schizophrenia
relative to those of healthy comparison subjects. Comparison
of the available school transcripts suggested that, even in the
first grade, children who later developed schizophrenia
manifested an average grade equivalent score approximately
0.8 year lower than healthy comparison subjects (selected to
have a similar distribution of age and gender) who did not
develop schizophrenia. Comparison of college aptitude test
scores (administered in grades 11 or 12) also indicated a
premorbid deficit, relative to healthy comparison subjects, of
almost one SD.
One caveat in interpreting Bilder et al.’s (2006) results
regarding school transcript and college aptitude test com-
parisons is that the healthy comparison groups had higher
mean parental social class scores than the patient group
(based on the Hollingshead-Redlich Index (Hollingshead
and Redlich 1958); also the healthy comparison group had a
higher proportion of Caucasians (approximately 49% of
patients and 83% of healthy comparison subjects were of
Caucasian background). The degree to which these socio-
economic and demographic differences affect the validity of
the archival scores in establishing premorbid cognitive
function is uncertain. Nonetheless, the overall pattern in
the literature is generally consistent with the findings from
Bilder et al.
Results of two meta-analytic reviews of studies doc-
umenting premorbid IQ among persons who subsequently
developed schizophrenia suggest presence of at least a mild
premorbid cognitive deficit, with an average premorbid Full
Scale IQ of 90 to 95 compared to the population mean of
100, with SD of 15 (Aylward et al. 1984; Woodberry et al.
2008). For instance, Woodberry et al. (2008) reviewed 18
studies in which people who later developed schizophrenia,
as well as healthy comparison subjects, had received
standardized IQ or similar psychometric tests (studies
focused on achievement tests were excluded) and found a
lower premorbid IQ with a medium effect size (d=0.54)
among people who later developed schizophrenia. Woodberry
et al. noted that this effect size is approximately half the
effect size found in comparison of IQ when measured
among post-onset schizophrenia patients relative to
healthy comparison subjects (Dickinson et al. 2007;
Heinrichs and Zakzanis 1998). It is also lower than the
mean effect sizes for WAIS Full Scale IQs among first
episode patients when compared against normal controls,
d=1.01 (Mesholam-Gately et al. 2009). But there was no
evidence of an age-related decline in IQ during the
premorbid period, and there was no significant difference
in the pattern of intellectual skills when considered in terms
of Verbal versus Performance IQ.
As noted by the previous discussion of cognitive
heterogeneity, much of the literature on premorbid
cognitive deficits among persons with schizophrenia has
focused on group averages, yet schizophrenia is typified
by substantial interpatient heterogeneity in virtually every
dimension along which this disorder may be characterized.
Thus it is not at all clear that the presence of premorbid
cognitive deficits typifies all persons who later develop
schizophrenia. Indeed, as previously noted in the discus-
sion of neuropsychologically normal persons with schizo-
phrenia, there may be some persons who functioned well
above average in premorbid cognitive abilities (Keefe et
al. 2005; Kremen et al. 2000; Wilk et al. 2005). Also,
generally consistent with theories of brain or cognitive
reserve (Satz 1993; Stern 2002), it is quite possible that
lower premorbid cognitive functioning, rather than reflect-
ing the influence of genetic or other schizophrenic
vulnerability, may represent a “second hit” to those
genetically at risk for schizophrenia, making the pheno-
typic expression of that risk as clinical schizophrenia more
likely (cf. Mednick and Hollister 1995).
Peri-onset cognitive changes: Data documenting the course
of cognitive deficits before and after onset of clinical
symptoms are relatively rare. One approach to examining
this issue is to study subpopulations who received pre-
morbid testing (such as aptitude tests administered as part
of enlistment in the military), and then to re-administer the
same tests at a post-onset period to people who did and who
did not develop schizophrenia or other neuropsychiatric
conditions. One of the earliest examples of this approach
was a study by Schwartzman and Douglass (Schwartzman
and Douglas 1962; Schwartzman et al. 1962), who
compared the premorbid Army enlistment test scores, as
well as 10-year re-test scores, of Canadian World War II
veterans, including 50 who developed schizophrenia some-
time after enlistment and 30 psychiatrically healthy veter-
ans, matched to the patient group in terms of test scores at
the time of enlistment. The authors found that the group
that developed schizophrenia evidenced a premorbid to
post-onset decline equivalent to approximately six IQ
points. A detailed review of this and other early longitudi-
nal studies is available in Heaton and Drexler (1987).
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A more recent study relevant to establishing the degree
of premorbid to post-onset cognitive decline associated
with schizophrenia is that of Seidman et al. (2006), who
examined changes in IQ of persons with schizophrenia
whose intellectual functioning had originally been assessed
at age seven as part of the final visit in the National
Collaborative Perinatal Project (NCPP). The latter was a
prospective national study in which 50,000 people were
followed periodically from the prenatal period through the
first seven years of life. Seidman et al. contacted a subset of
participants approximately 28 years later and re-
administered intelligence tests. Their report provides a
longitudinal comparison of IQ test performance from age
seven to an approximate 28-year follow-up among 38
people who developed schizophrenia or schizoaffective
disorder and 62 non-schizophrenic controls. Consistent
with findings reviewed above regarding premorbid func-
tioning, persons who developed schizophrenia had lower
IQ scores when tested as children relative to the non-
schizophrenic controls; moreover, the persons with schizo-
phrenia, on average, showed a decline of approximately 10
IQ points (adjusted for changes seen in the control group)
from age seven to the time when they were re-tested in their
30s. One interpretive caution regarding the latter finding,
however, is that when comparing childhood to adult IQ
scores, it can be difficult to disentangle a failure to show
normative maturation/development of cognitive skills from
an actual within-person decline in cognitive efficiency
(Wechsler 1939).
Taken together, the admittedly limited longitudinal
premorbid to postmorbid cognitive comparisons suggest
that, on average, schizophrenia illness onset may be
associated with one-third to one-half SD decline in general
cognitive functioning.
Post-onset cognitive course: Neither the presence of pre-
morbid cognitive deficits nor the occurrence of an initial
further decline in overall cognitive functioning around the
time of clinical onset of schizophrenia has generated
particular controversy. There has been somewhat less
consensus regarding the long-term course of cognitive
deficits after onset of illness, but even in that regard, a
general agreement appears to be emerging that, contrary to
Kraepelin’s initial suggestion that dementia praecox is
characterized by a course of progressive decline, the
cognitive deficits in schizophrenia tend to stabilize (Heaton
et al. 2001; Kurtz 2005; Rund 1998), and may even
partially improve during the initial stabilization phase
immediately after first onset (Albus et al. 2002; S. Kristian
Hill et al. 2004; Klingberg et al. 2008).
Longitudinal as well as cross-sectional studies of non-
institutionalized patients consistently demonstrate stable
cognitive deficits after illness onset (Heaton et al. 1994,
2001; Kurtz 2005; Rund 1998). An example of the
remarkable stability in neurocognitive functioning associ-
ated with schizophrenia was provided in a longitudinal
study from our research group (Heaton et al. 2001) in
which 142 patients with schizophrenia and 209 healthy
comparison subjects were re-tested with an expanded
Halstead-Reitan test battery for an average of three years
(and up to 10 years). We found no evidence of cognitive
decline in any of seven neurocognitive ability areas
examined. Moreover, there were no differences in stability
of cognitive functioning when considered in reference to
shorter versus longer-term follow-up, lower versus higher
baseline functioning, age of onset, elderly versus non-
elderly baseline age, or when patients were categorized by
stability or change in severity of positive or negative
symptoms.
A possible exception to the general rule of cognitive
stability in schizophrenia is the case of elderly persons who
have experienced long-term institutionalization for schizo-
phrenia (reviewed in Kurtz 2005; Rajji and Mulsant 2008;
White et al. 2006). There does seem to be a greater decline
in general cognitive functions than can be attributed to
“normal aging” in a subgroup of such patients. This decline
does not seem to be attributable to a comorbid neurode-
generative condition such as Alzheimer’s disease (Friedman
et al. 1999). One difficulty in interpreting such findings is
that the effects of institutionalization alone are difficult to
disentangle from the specific effects of schizophrenia
requiring institutionalization. That said, an association
between chronic institutionalization for schizophrenia and
cognitive decline was observed even in some of the earliest
longitudinal studies of cognitive changes in schizophrenia
(e.g., Schwartzman et al. 1962). Nonetheless, as the bulk of
contemporary patients with schizophrenia have not been
chronically institutionalized (Cohen et al. 2000; Vahia et al.
2007), it appears that the modal pattern is one of
remarkable long-term cognitive stability in the post-onset
period.
Neuropathology
Precise delineation of the neuropathology underlying
schizophrenia in general, or its associated neurocognitive
deficits in particular, have both remained elusive despite
efforts extending back over a century. There are some
general patterns reviewed below.
Brain MRI studies of schizophrenia have found lower
gray matter volumes (especially in the superior temporal
gyrus and in medial temporal lobe and limbic structures
including the amygdala, hippocampus, and parahippocam-
pal gyrus), volume reductions in the frontal and parietal
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lobes, lack of normal asymmetries, enlargement of the
caudate (perhaps related to medication), and developmental
abnormalities such as presence of cavum septum pelluci-
dum [thought to reflect aberrations in neurodevelopment;
patients with larger cavum septum pellucidum may show
worse performance on learning and other cognitive meas-
ures (Flashman et al. 2007)]. There are also frequent
abnormalities in the size or shape of the corpus callosum
(Price et al. 2007; Walterfang et al. 2008), supporting the
view of schizophrenia as a disconnection syndrome (Friston
and Frith 1995) and, as with earlier CT findings, there are
enlarged ventricles (DeLisi 2008; Shenton et al. 2001).
Functional imaging studies have found lower activity in
the prefrontal cortex and abnormal activation in the
temporal lobes during performance of both verbal and
visual tasks (Eyler et al. 2004, 2008; Keshavan et al. 2008).
This finding is also true for PET and SPECT, where the
literature suggests problems in the prefrontal and temporal
regions of the brain (Lawrie et al. 2008). In resting state
network studies using fMRI, results are mixed as to the
effect that schizophrenia has on connectivity (Greicius
2008). Overall, the main areas that are implicated in both
resting state and activation-based fMRI studies on an
assortment of cognitive-based tasks include parts of the
cerebral cortex (i.e., prefrontal, cingulate and temporal
areas), the limbic system (specifically the hippocampus,
striatum and thalamus), and the cerebellum (McGuire et al.
2008).
Additional information has come through studies employ-
ing Diffusion Tensor Imaging (DTI), which measures the
fractional anisotropy of white matter tracts (i.e., how intact the
tracts are). In schizophrenia, rather consistent findings are
abnormalities in these tracts, leading to increased diffusivity in
the prefrontal and temporal lobes, corpus callosum, uncinate
fascicules, cingulum bundle, and arcuate fasciculus (Assaf and
Pasternak 2008; Kubicki et al. 2007). The white matter
findings of Wexler et al. (2009), described above in the
section on neuropsychologically normal schizophrenia, sug-
gested abnormalities of functional connectivity in participants
with schizophrenia and cognitive impairment, but not in
healthy controls or participants with schizophrenia and no
cognitive impairment.
Other significant central nervous system findings in
schizophrenia are in neurochemical dysfunction (e.g.,
reduced N-acetyl aspartate in the frontal and temporal
lobes, hypercortisolemia and hypothalamo–pituitary–adre-
nal axis dysregulation, and an increase in D2 receptors in
the striatum), neurophysiological dysfunction (including
abnormal prepulse inhibition, decreased P300 amplitudes,
and REM sleep abnormalities), and at autopsy, decreased
dendritic density accompanied by normal or increased
neuron density and an absence of gliosis (Keshavan et al.
2008).
Effects on Everyday Functioning
There has been long-standing interest in the functional
importance of neurocognitive deficits in schizophrenia.
More than 30 years ago, the senior author of the present
review (RKH) noted “The clinical value of neuropsycho-
logical evaluation would be increased considerably if it
could also provide some reliable information regarding the
patient’s abilities to meet the demands of his [or her]
everyday life” (Heaton 1976, p. 11). A wealth of empirical
research relevant to establishing such clinical value in
multiple clinical and nonclinical populations has arisen in
the subsequent three and a half decades (Green 1996; Green
et al. 2000; Heaton and Pendleton 1981; Kurtz 2006). In
particular, the empirical literature is quite clear and
consistent in demonstrating that, whereas the positive
symptoms of schizophrenia have little or no demonstrable
effect on everyday functioning, the neurocognitive deficits,
and to lesser degree negative symptoms, are significant
correlates of functional capacity, and (perhaps less directly)
levels of manifest everyday functioning.
The issue of whether there are differential effects of
impairment in specific cognitive domains on overall function-
al capacity or status is less clear. In Green’s (1996) classic
review of this literature, he divided the types of functional
capacity, status, or outcome variables into three categories:
(a) independence in community functioning, (b) social
problem solving, and (c) skill acquisition. The strongest
evidence for significant cognitive correlates was with tests of
auditory episodic memory (which Green labeled “secondary
verbal memory”), for which at least some studies found
significant correlations with community functioning, social
problem solving, and skill acquisition. The evidence regard-
ing an association with executive functions (as assessed with
Wisconsin Card Sorting Test [WCST]) was strong for
community functioning, weaker for skill acquisition, and
non-significant for social problem solving. The evidence for
vigilance (as measured with a Continuous Performance Test)
was strong for social problem solving and skill acquisition,
but absent (not assessed) for community functioning. Green
concluded that auditory memory and vigilance appear to be
necessary for adequate functional outcome.
One might be tempted to interpret these reviewed
findings as indicative of differential importance of specific
cognitive dimensions, but Green (1996) himself was careful
to note that his conclusions were limited by the infrequency
with which specific associations had actually been assessed
and reported in the empirical literature. Moreover, in a
subsequent updated review of the literature, Green et al.
(2000) found that the largest amount of variance (between
20 and 60 percent) in functional outcome was predicted by
global or composite cognitive (rather than domain-specific)
measures of neurocognition. This is not surprising because,
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as discussed above, schizophrenia is typically associated
with multiple deficits in varying patterns, rather than with
any single isolated cognitive impairment. In addition, with
the larger number of studies available in the 2000 review,
Green et al. (2000) found further evidence that the strength
of documented associations may be influenced by the
frequency with which the associations have been examined
in the literature. For example, the updated review found
studies in which executive functions (WCST scores) were
associated with social problem solving, in addition to skill
acquisition and community functioning.
Results of several studies from our research group and
others suggest that the association between cognitive
deficits and impairments in functional capacity or status
are generally non-specific (Evans et al. 2003; Palmer et al.
2002; Palmer and Jeste 2006; Twamley et al. 2002; Velligan
et al. 2000). Such findings do not necessarily mean that
there are no differential relationships between specific
cognitive deficits and specific functional tasks. However,
efforts to unequivocally document the presence and nature
of such relationships are hampered by the multi-factorial
nature of standard neurocognitive tests (Dickinson and
Gold 2008; Gladsjo et al. 2004; The Psychological
Corporation 1997), the multifactorial nature of most
everyday tasks and activities, the lack of neurocognitive
(as well as functional outcome) tests of different domains
that have documented psychometric equivalence (Chapman
and Chapman 1973), the above mentioned heterogeneity of
cognitive profiles of schizophrenia, and differences in
opportunity of patients to perform certain everyday tasks
and activities (Bellack et al. 2007).
The last decade also brought increased interest in the
degree to which the association between the cognitive
deficits and functional disability associated with schizo-
phrenia might be exceeded or partially mediated by deficits
in what has been called “social cognition” (Green et al.
2000; Green and Leitman 2008; Kee et al. 1998), a term
which in the context of schizophrenia research has been
defined as referring to the following constructs: theory of
mind (requiring inferences about the mental states of
others), social perception, social knowledge, attributional
biases, and emotional processing (see Green et al. 2008). [It
should be noted that such use of the term “social cognition”
is narrower than originally developed within the field of
social psychology, wherein it includes a broader array of
constructs such as perceived self-efficacy, outcome expec-
tancies, and perceived locus of control (e.g., Bandura 1986;
Mischel 1973; Rotter 1966)]. Accumulating evidence
supports the contention that persons with schizophrenia,
and even first-degree relatives, may show deficits in at least
some of these social cognitive dimensions (Bora et al.
2009; Eack et al. 2009; Marwick and Hall 2008), and that
they do indeed affect functional outcome (Couture et al.
2006). Research is ongoing, but the body of published
research in which identical constructs have been examined
is presently too small to draw firm conclusions regarding
the degree to which social cognitive deficits supplement,
supplant, or mediate the effects of “generic” neurocognition
on everyday function (Bowie et al. 2008; Pijnenborg et al.
2009; Vauth et al. 2004). It appears likely that some of the
effects of cognition on outcome will be mediated through
social cognitive abilities, but that not all aspects of
everyday functioning depend on social efficiency or skill.
Treatment
Pharmacologic: The era of conventional neuroleptics be-
gan when the antipsychotic properties of chlorpromazine
were first identified in France in 1952; chlorpromazine
received FDA approval two years later in March 1954
(Crilly 2007). Although chlorpromazine and other subse-
quently developed neuroleptic medications were eventually
found to have serious potential side-effects such as tardive
dyskenisia (reviewed in Jeste et al. 1999), they were
generally thought to have minimal effects on cognition
(either positive or deleterious), with the possible exception
of partial normalization of some aspects of attention (e.g.,
Cassens et al. 1990; Spohn and Strauss 1989). However,
Mishara and Goldberg (2004) noted that this “general
wisdom” about the lack of beneficial effects of conven-
tional neuroleptic medications on cognitive deficits in
schizophrenia was based exclusively on narrative reviews
of the empirical literature, i.e., there was no extant
quantitative/meta-analytic review. The latter authors con-
ducted a meta-analyses of the available empirical literature
and found, contrary to conventional wisdom, that that
there might indeed be some beneficial neurocognitive
effects of conventional neuroleptic medications which,
while modest in size (mean effect size d=0.22), at least
warrant further empirical inquiry (Mishara and Goldberg
2004).
The era of “atypical” or “second generation” antipsy-
chotic medications is a long and circuitous one dating back
to the late 1950s (Crilly 2007; Hippius 1999), but
systematic study of the effects of second generation
antipsychotic medications on the neuropsychological defi-
cits in schizophrenia began in the early to mid-1990s. The
subsequent decade brought some suggestions that second
generation antipsychotic medications might partially im-
prove certain aspects of neurocognitive functioning
(Harvey and Keefe 2001; Keefe et al. 1999; Meltzer and
McGurk 1999; Woodward et al. 2005). However, whether
atypical antipsychotic medications actually produce func-
tionally relevant degrees of cognitive benefit remains a
point of debate (Carpenter and Gold 2002).
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The largest and most comprehensive investigation of the
cognitive effects of antipsychotic medications was provided
by the NIMH-sponsored Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) schizophrenia study
(Keefe et al. 2007). The CATIE study involved a randomized
double-blind comparison of schizophrenia treatment for up to
18 months with any of five medications, including four
second generation antipsychotics (olanzapine, quetiapine,
risperidone, or ziprasidone) and one conventional neuroleptic
(perphenazine). The cognitive effectiveness analyses were
based on 817 patients who completed at least a baseline and 2-
month follow-up assessments. There was a significant
improvement in overall cognitive performance within each
of the treatment groups, and there were no significant
differences between the treatment groups in terms of changes
in any of five specific cognitive domains. Similar findings
were seen in the subset of participants for whom 6- or 18-
month follow-up data were available. The difference in
cognitive scores from 2- to 18-months was negligible,
suggesting the bulk of improvement occurred in the first two
months of treatment. Overall changes in each of the groups,
while statistically significant, were small and of questionable
functional importance, and given the absence of an untreated
group, could at least partially reflect practice effects. If
anything, however, participants randomized to the conven-
tional neuroleptic manifested greater improvement in cogni-
tive performance than did those randomized to second
generation antipsychotics. Specifically, exploratory pairwise
comparisons of 18-month change scores suggested that
improvement in the neurocognitive composite score was
better in the group randomized to treatment with the
conventional neuroleptic (perphenazine) relative to those
randomized to treatment with olanzapine or risperidone.
One important interpretive caveat mentioned by Keefe et
al. (2007) was that the majority of patients in the CATIE
study were already receiving treatment with one or more
antipsychotic medications at the time of study entry. The
overall pattern of results did not change even when the
investigators adjusted the analyses to account for patients’
reports of their baseline antipsychotic medication; nonethe-
less, the possibility cannot be ruled out that acute cognitive
benefits of second generation antipsychotic medications may
have been attenuated by prior treatment with the same
medication. Even so, such experience would not explain the
(unexpected) finding of cognitive benefits from the conven-
tional neuroleptic, perphenazine. The findings from more
recent report from the European First Episode Schizophrenia
Trial also suggest no differential cognitive benefit of second
generation antipsychotics versus conventional neuroleptics
(Davidson et al. 2009). In the latter study, 498 first episode
schizophrenia patients (each with less than 2 weeks exposure
to antipsychotic medications in the year preceding study
enrollment) were randomly assigned to treatment with a
conventional neuroleptic (haloperidol) or one of four second
generation antipsychotic medications (amisulpride, olanza-
pine, quetiapine, or ziprasidone). Comparison of baseline to
6-month follow-up assessments indicated statistically signif-
icant improvements in overall cognitive test performance,
but there were no differences in the magnitude of the
changes among the five medication groups.
The question of differential cognitive benefits of second
generation versus conventional neuroleptic medications is not
fully settled (Woodward et al. 2005, 2007). In light the
documented effect sizes, however, there appears little reason
to be very enthusiastic about the cognitive benefits of either
class of medication. On the other hand, this conclusion
relates only to the potential cognitive effects of medications
intended primarily to treat the psychotic symptoms. Efforts
to develop more targeted pharmacologic treatments for
cognition in schizophrenia are represented by the NIMH-
sponsored Measurement and Treatment Research to Improve
Cognition in Schizophrenia (MATRICS), Treatment Units
for Research on Neurocognition and Schizophrenia
(TURNS), and Cognitive Neuroscience Treatment Research
to Improve Cognition in Schizophrenia (CNTRICS) projects
(Buchanan et al. 2007; Carter et al. 2008; Green 2007;
Marder 2006). Although development of drugs targeting
cognitive deficits in schizophrenia remains in the early
stages, these initiatives represent an important step forward
toward identification and development of promising com-
pounds or targets, to be tested by systematic efficacy and
effectiveness trials, and hopefully culminating in eventual
regulatory approval of safe and effective medications for this
key component of the illness.
Cognitive rehabilitation: In recent years, there has been an
increasing recognition of the need for psychosocial reha-
bilitative interventions for schizophrenia (Insel 2009). In
that regard, recent efforts to develop cognitive training
programs for schizophrenia offer promise (Twamley et al.
2003; Velligan et al. 2006). In general, these interventions
tend to be most effective when focused on teaching patients
compensatory strategies (i.e., to help patients identify ways
of minimizing the deleterious influence of cognitive
deficits, and to draw upon any cognitive or environmental
strengths that may be available). For example, Elizabeth
Twamley, with other colleagues in our research group,
recently developed a manualized 12-week cognitive reha-
bilitation program focused on teaching of compensatory
strategies and habit learning, and pilot tested its efficacy
(relative to pharmacotherapy alone) through a randomized
controlled trial (Twamley et al. 2008). At the post-treatment
assessment, those in the cognitive training group reported
fewer cognitive problems and more use of compensatory
strategies than those in the pharmacotherapy-alone group.
Replication and refinement is needed, but this study
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illustrates the importance and viability of looking beyond
pharmacologic interventions to address the functional
effects of neurocognitive deficits in schizophrenia. (Please
see Medalia and Choi (2009), this volume, for a compre-
hensive review of cognitive remediation in schizophrenia.)
Summary and Conclusions
Application of a neuropsychological perspective to the
study of schizophrenia has established a number of
important facts about this disorder. Some of the highlights
and key conclusions that can be drawn from our review of
this literature are summarized in Table 1, top among which
are that there is (a) substantial interpatient heterogeneity in
cognitive function, (b) remarkable cognitive stability over
the course of the illness, and (c) that severity of cognitive
deficits, not psychopathologic symptoms, seems to be the
primary determinant of impairments functional capacity and
functional status. The heterogeneity in cognitive function-
ing provides tangible reason to express hope to patients and
their families that schizophrenia is by no means typically
accompanied by profound cognitive deficits or by a lifelong
progressive decline in functioning. Thus contemporary data
provide a substantially more optimistic picture than that
portrayed by the classic Kraeplinian notion of schizophre-
nia as a dementia praecox. Recognition of the functional
effects of cognitive deficits has been important in directing
treatment development efforts away from the previous
exclusive focus on reduction or management of psychotic
symptoms, and toward a broader consideration of the need
for interventions that beneficially influence effects of the
cognitive deficits and negative symptoms that may be more
important determinants of residual disability.
One other tangible benefit of this body of research is that it
further establishes the view of schizophrenia as a neuro-
biologic disorder. Although neurobiologic models of schizo-
phrenia date back to its earliest conceptualization, the 20th
century also witnessed periods in which purely psychogenic
models dominated the field. The latter models sometimes had
the inadvertent effect of reinforcing the stigma experienced by
patients with this disorder and their families. For instance, the
“schizophrenogenic mother” theory was a particularly noto-
rious psychogenic model that often contributed to unwarrant-
ed guilt among family members about the affected person’s
condition (reviewed in Hartwell 1996).
Where should the field go from here? One consistent
issue that strikes us is the difficulty in firmly establishing the
presence of differential cognitive deficits in terms of specific
cognitive domains or patterns. As noted in our introductory
comments, one of the key motivating factors or assumptions
behind much of the contemporary neuropsychological
research in schizophrenia has been the hope/assumption that
specification of the neurocognitive pattern(s) associated with
schizophrenia may help clarify the neuroanatomic and/or
neurophysiologic regions or systems that underlie expression
of this disorder (Levin et al. 1989). While the data seem to
point to some degree to temporal and frontal-subcortical
brain systems, these were among the regions Kraepelin
(1971/1919/1913) himself expressed interest in almost a
century ago, and which were reiterated by others, such as in
the previously cited quote from Kurt Goldstein in 1939
(Goldstein 1939). Judged from that perspective, the degree
of progress is unimpressive.
Closely related to the difficulty in establishing differen-
tial cognitive deficits characterizing schizophrenia is the
question of specificity. That is, given that one of the reasons
to consider the pattern(s) of neuropsychological strengths
and weaknesses associated with schizophrenia is to under-
stand the underlying neurobiology associated with mani-
festation of the clinical syndrome, it would be helpful to
discern the degree to which the level and pattern(s) of
neurocognitive deficits associated with schizophrenia are
distinct from those of other forms of serious mental illness,
such as schizoaffective disorder or bipolar disorder. With a
few isolated exceptions, most studies comparing level,
pattern, and frequency of neurocognitive deficits among
patients with schizophrenia versus schizoaffective disorder
suggest no reliable differences (reviewed in Palmer and
Savla 2009). [Recent reports on preparation of the DSM-V,
scheduled for publication in 2012, indicate plans to
eliminate schizoaffective disorder as diagnostic entity
separate from schizophrenia (Gever 2009).] Comparisons
of persons with schizophrenia to those with bipolar disorder
have led to a more complex pattern of results. In an
interesting contrast to schizophrenia, in which duration of
illness, symptom severity, and fluctuations of symptoms do
not substantially influence severity of cognitive deficits
(Heaton et al. 1994, 2001; Nayak et al. 2006; Palmer et al.
1997), a number of studies suggest that some cognitive
functions are adversely affected by severity of current
manic or depressive symptoms in bipolar patients (reviewed
in Goldberg and Burdick (2008)). However, cognitive
deficits are also present during the inter-episode periods
of relative remission/euthymia among many persons with
bipolar disorder (Cavanagh et al. 2002; Martinez-Aran et al.
2004a, b; Torrent et al. 2006). These deficits may be worse
among patients with a longer duration of illness and with
higher numbers of lifetime affective episodes (Bearden et
al. 2001; Cavanagh et al. 2002; Denicoff et al. 1999;
El-Badri et al. 2001; Lebowitz et al. 2001; Zubieta et al.
2001). Yet, the primary finding in comparison of neuro-
psychological profiles among persons with schizophrenia
versus bipolar disorder is that those with bipolar disorder
tend to have a similar profiles of impairment, but have a
Neuropsychol Rev (2009) 19:365–384 377
less severe degree of impairment (Depp et al. 2007;
Schretlen et al. 2007; Seidman et al. 2002).
Much of the existing research on cognitive deficits in
schizophrenia also was motivated by a general presumption
that identifying cognitive strengths and weaknesses within
persons with schizophrenia, and the relationship of such
cognitive abilities/deficits to psychosocial or independent
functions, would have clinical value in developing effective
placement and rehabilitation plans. While the relationship
between cognitive function in general and functional capacity
is firmly established, the evidence for differential relationships
between specific cognitive dimensions and specific tasks or
demands of everyday living remains murky.
In part, the difficulties in making greater progress in
establishing the presence of differential cognitive deficits
and differential relationships with specific aspects of
everyday functioning may reflect the heterogeneous nature
of schizophrenia. Eugen Bleuler (1950/1911) appears to
have been wise in describing the disorder with the plural
(“schizophrenias”) rather than singular (“schizophrenia”)
form. It is possible that further advances in neuroimaging,
genomics, and epigenetics will help identify more homog-
enous neurocognitive subtypes than are presently available.
Also, Kremen et al. (2000) noted that “examination of
individual neuropsychological profiles could be a useful
alternative to group analysis for making sense of heteroge-
neity in schizophrenia” (p. 744). One patient may evidence
difficulty on a list learning task due to impairments in
memory consolidation associated with medial temporal
lobe dysfunction, whereas another patient’s poor perfor-
mance on that same task may reflect deficits in frontal or
frontal-subcortical systems related executive functions, e.g.,
resulting in choice and application of a suboptimal
encoding strategy. In recognition of such possibilities, in
clinical interpretation, neuropsychologists do not typically
or automatically interpret tests as measures of their named
or standard cognitive constructs, but rather attempt to come
up with hypotheses of the latent deficit(s) that may explain
Table 1 Summary of key findings from the empirical literature on neuropsychological aspects of schizophrenia
Domain of inquiry Key findings
Level of impairment Heterogeneous findings between persons, between domains, and between studies, but on average, schizophrenia is
associated with a mild-to-moderate degree of cognitive deficit approximately one standard deviation below the
normative mean
Pattern Generalized impairment in most cognitive domains; some evidence of stronger effect sizes for aspects of immediate
recall on episodic declarative memory tasks, and for processing speed, with lower (but still medium to large) effect
sizes in reference to crystallized knowledge and visual-spatial skills. There is little consistent evidence of
differential decline in working memory or executive functions, despite long-standing interest in these domains as
potential core deficits in schizophrenia.
Heterogeneity About 20% to 25% of patients with schizophrenia retain a psychometrically normal pattern of neurocognitive
functions. Neuropsychologically normal status does not appear to represent differences in severity of illness, as
reflected by psychotic symptoms. Cluster analytic studies also suggest the presence of a severely impaired
subgroup, which would be consistent with earlier notions of deficit syndrome, Type II, and/or negative symptom
schizophrenia.
Course Mild (on average) premorbid cognitive deficits; further decline at the time of onset of clinical symptoms equivalent
to about 5 to 10 IQ points (with partial recovery of cognitive functions during the stabilization phase after first
onset); a stable pattern of cognitive functions across all neurocognitive domains over the long-term chronic course
among non-institutionalized patients
Neuropathology Precise delineation of the neuropathology underlying schizophrenia in general, or its associated neurocognitive
deficits in particular, has remained elusive despite efforts extending back over a century. However, general patterns
include decreased gray matter volume (particularly in the temporal and limbic structures), as well as enlarged
caudate and ventricles. Functional imaging studies suggest decreased activity in the prefrontal cortex and abnormal
activation in the temporal lobes during both verbal and visual tasks. Diffusion Tensor Imaging (DTI) studies
suggest schizophrenia may be associated with increased diffusivity, in the prefrontal and temporal lobes, corpus
callosum, uncinate fascicules, cingulum bundle and arcuate fasciculus.
Effects on everyday
functioning
Positive symptoms of schizophrenia have little effect on everyday functioning. Neurocognitive deficits, and to lesser
degree negative symptoms, are significant correlates functional capacity, and to a lesser degree levels of manifest
everyday functioning. Little compelling evidence of differential associations between specific cognitive deficits and
impairments in specific dimensions of functional capacity or status. Whether and the degree to which, or under
what specific conditions, the association between cognitive deficits and deficits in everyday functioning are
supplemented by, supplanted by, or mediated by the effects on social competence related skills (“social cognition”)
remains an open question.
Amenability to treatment Relative cognitive benefits of conventional versus second generation antipsychotic medications remains a point of
unresolved debate, but none has been shown to result in substantial (functionally relevant) levels of cognitive
improvement. Efforts are ongoing to develop pharmacologic agents that would directly target the cognitive deficits
associated with schizophrenia, as well as to develop and validate non-pharmacologic cognitive compensatory programs.
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the pattern of strengths and weaknesses across a set of tests.
Yet in neurocognitive research there is a tendency to equate
deficits on specific test scores with their labeled ability. The
apparent diffuse or nonspecific nature that seems to best
characterize the “average” pattern of neurocognitive deficits
in schizophrenia may, at least in part, reflect the fact that we
(as a field) tend to blend “apples and oranges” and then try
to say something intelligent about “average” fruit. Further
advances in analytic methodology may enable researchers
to more effectively apply process or idiographic interpreta-
tion to large sets of cognitive data from schizophrenia
patients and their subgroups (cf. Barlow and Nock 2009).
In addition, there remains a need for better neurocognitive
measures that are more sensitive and specific to deficits in
discrete cognitive functions. Many of the commonly used
cognitive measures have shown relatively little modification
from their original forms over the past 50 to 100 years (Berg
1948; Boake 2000, 2002; MacLeod 1991; Partington and
Leiter 1949; Wechsler 1939). These are all well-established
tools, and remain valued components of the neuropsycho-
logical armory, but it must also be recognized that they were
generally developed and designed for uses quite distinct
from establishing differential cognitive deficits in neuropsy-
chiatric conditions. There is reason for optimism that the tide
is turning in this regard. In particular, the Cognitive
Neuroscience Treatment Research to Improve Cognition in
Schizophrenia (CNTRICS) initiative is a recent cognitive
neuroscience focused spin-off of the more widely known,
clinically construct-oriented MATRICS project (Carter et al.
2008). The aim of the CNTRICS is to identify promising
constructs from cognitive neuroscience which may be useful
in identifying more specific or elementary cognitive process-
es related to more specific brain systems involved in
schizophrenia. Whether the products of this initiative will
in fact lead to more sensitive and specific measures of
differential cognitive abilities/deficits in schizophrenia is
uncertain, but it seems a timely and worthy attempt.
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